Fig. 5
FMD alleviates inflammatory pain by inhibiting the formation of NETs. A. Schematic of the experimental timeline. B. Paw withdrawal threshold of mice in each group (n = 6, group: F4, 20 = 93.84, P < 0.0001; time: F4, 20 = 48.47, P < 0.0001; interaction: F16, 80 = 11.22, P < 0.0001). C. Paw withdrawal latency of mice in each group (n = 6, F4, 20 = 135.1, P < 0.0001; time: F (4, 20) = 181.2, P < 0.0001; interaction: F (16, 80) = 23.48, P < 0.0001). D and E. Representative blots and quantification of MPO and citH3 in the spinal cords of vehicle, FMD, FMD + CI-amidine, and FMD + PMA groups (n = 5, MPO: F (3, 16) = 28.97, P < 0.0001; citH3: F (3, 16) = 20.67, P < 0.0001). F. Double immunofluorescence staining for citH3 (red) and MPO (green) in the spinal cords. NETs visualized by colocalization of citH3 and MPO staining (merged images; n = 3, scale bars: 50 or 100 μm). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with the vehicle mice. #P < 0.05, compared with the FMD group mice. & P < 0.05, compared with the CI-amidine group mice